PGDx elio™ tissue complete

The CE-IVD marked marked tumor profiling kitted solution

Get Started Today
Get started today!
By filling in this form, you affirm that you have read and understand the Privacy Policy and Terms of Use
Success!
Success Icon

Thank you for your submission.

PGDx elio TISSUE COMPLETE

Rapid and actionable insights.

Personalized care.

Designed for in-house comprehensive tumor profiling, the PGDx elio tissue complete solution delivers actionable results with a clinical success rate of greater than 92%.

Trustworthy

CE-IVD marked and FDA-cleared

Robust

Automated results with a clinical success rate of greater than 92%

Actionable

500+ solid tumor-related genes, with easy-to-interpret reports clearly highlighting genetic alterations that could impact care decisions

Accessible

Retain complete control over specimens and data

PGDx elio TISSUE COMPLETE

Product overview

Product Brochure

Benefits of the PGDx pan solid tumor CGP test

Equip your lab to deliver better insights

PGDx elio tissue complete enables you to confidently advise your oncologists and gain new research advantages with our sample-to-answer CE-IVD kit that includes fully automated bioinformatics and dedicated customer support.

See Sample Report

Our test, your lab

Offer rapid comprehensive, scalable genomic testing and report on actionable findings with confidence with 5 day* turnaround from isolated nucleic acid to variant report.

Accelerate your path to test launch and reimbursement

CE-marked and FDA-cleared solution allows for verification, not validation. Professional services available with dedicated implementation project management with custom script development enables seamless integration. Go-live in 6 weeks.

Enable new opportunities

Activate new research opportunities and unlock new potential paths to reimbursement.

505

Gene panel with TMB and MSI

35

Solid tumor types

CE-marked

FDA-cleared

5

Days from isolated nucleic acid to variant report*

6

Weeks to go live

92%

Clinical success rate

*Kitted workflow plus pipeline output. Not inclusive of DNA extraction and downstream processing

Backed by robust bioinformatics
Empowering local insight for oncology
Product Brochure
TESTIMONIALS

Market leaders choose PGDx elio™ tissue complete

Quote Icon

The PGDx team provided excellent project management during the onboarding and implementation process, allowing for only 196 days from contract signed to first patient report.

US Pathologist, Lab Director
TECHNICAL INFORMATION
PGDx elio tissue complete product specs

This test identifies somatic mutations with high accuracy and sensitivity, providing information on single nucleotide variants (SNVs), insertions/​deletions (indels), amplifications, translocations, microsatellite instability (MSI) status and tumor mutation burden (TMB) for use by qualified professionals to guide treatment decisions.

Product Brochure
 Lab Verification Example
 Gene List

Resources

CUSTOMER PORTAL
Review technical documents
& sample reports
Login
SUPPORT
Get help now
Learn More

Patent Disclaimer

For In Vitro Diagnostic Use.
Personal Genome Diagnostics Inc. (PGDx) is a subsidiary of Laboratory Corporation of America Holdings, using the brand Labcorp.
©2023 Laboratory Corporation of America® Holdings. All rights reserved.